img

Global Vaccine for Influenza Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Vaccine for Influenza Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
The global Vaccine for Influenza market size was US$ 5505 million in 2022 and is forecast to a readjusted size of US$ 7088.2 million by 2034 with a CAGR of 3.6% during the forecast period 2024-2034.
Global Flu Vaccine key players include Sanofi Pasteur, CSL, GSK, etc. Global top three manufacturers hold a share over 75%.
North America is the largest market, with a share about 40%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.
In terms of product, Quadrivalent Influenza Vaccine is the largest segment, with a share nearly 85%. And in terms of application, the largest application is For Adults and Children over 3 years, followed by For Children (6 months to 3 years).
In terms of sales (consumption) side, this report focuses on the sales of Vaccine for Influenza by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Vaccine for Influenza market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Vaccine for Influenza market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Sanofi
CSL
GSK
Mylan
Hulan Bio
AstraZeneca
CCBIO
By Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
By Application
For Children (6 months to 3 years)
For Adults and Children over 3 years
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Vaccine for Influenza in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Vaccine for Influenza manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine for Influenza sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Vaccine for Influenza Definition
1.2 Market by Type
1.2.1 Global Vaccine for Influenza Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Market Segment by Application
1.3.1 Global Vaccine for Influenza Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 For Children (6 months to 3 years)
1.3.3 For Adults and Children over 3 years
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Vaccine for Influenza Sales
2.1 Global Vaccine for Influenza Revenue Estimates and Forecasts 2018-2034
2.2 Global Vaccine for Influenza Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Vaccine for Influenza Revenue by Region
2.3.1 Global Vaccine for Influenza Revenue by Region (2018-2024)
2.3.2 Global Vaccine for Influenza Revenue by Region (2024-2034)
2.4 Global Vaccine for Influenza Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Vaccine for Influenza Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Vaccine for Influenza Sales Quantity by Region
2.6.1 Global Vaccine for Influenza Sales Quantity by Region (2018-2024)
2.6.2 Global Vaccine for Influenza Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Vaccine for Influenza Sales Quantity by Manufacturers
3.1.1 Global Vaccine for Influenza Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Vaccine for Influenza Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Vaccine for Influenza Sales in 2022
3.2 Global Vaccine for Influenza Revenue by Manufacturers
3.2.1 Global Vaccine for Influenza Revenue by Manufacturers (2018-2024)
3.2.2 Global Vaccine for Influenza Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Vaccine for Influenza Revenue in 2022
3.3 Global Vaccine for Influenza Sales Price by Manufacturers
3.4 Global Key Players of Vaccine for Influenza, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaccine for Influenza, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaccine for Influenza, Product Offered and Application
3.8 Global Key Manufacturers of Vaccine for Influenza, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Vaccine for Influenza Sales Quantity by Type
4.1.1 Global Vaccine for Influenza Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Vaccine for Influenza Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
4.2 Global Vaccine for Influenza Revenue by Type
4.2.1 Global Vaccine for Influenza Historical Revenue by Type (2018-2024)
4.2.2 Global Vaccine for Influenza Forecasted Revenue by Type (2024-2034)
4.2.3 Global Vaccine for Influenza Revenue Market Share by Type (2018-2034)
4.3 Global Vaccine for Influenza Price by Type
4.3.1 Global Vaccine for Influenza Price by Type (2018-2024)
4.3.2 Global Vaccine for Influenza Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Vaccine for Influenza Sales Quantity by Application
5.1.1 Global Vaccine for Influenza Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Vaccine for Influenza Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
5.2 Global Vaccine for Influenza Revenue by Application
5.2.1 Global Vaccine for Influenza Historical Revenue by Application (2018-2024)
5.2.2 Global Vaccine for Influenza Forecasted Revenue by Application (2024-2034)
5.2.3 Global Vaccine for Influenza Revenue Market Share by Application (2018-2034)
5.3 Global Vaccine for Influenza Price by Application
5.3.1 Global Vaccine for Influenza Price by Application (2018-2024)
5.3.2 Global Vaccine for Influenza Price Forecast by Application (2024-2034)
6 North America
6.1 North America Vaccine for Influenza Sales by Company
6.1.1 North America Vaccine for Influenza Revenue by Company (2018-2024)
6.1.2 North America Vaccine for Influenza Sales Quantity by Company (2018-2024)
6.2 North America Vaccine for Influenza Market Size by Type
6.2.1 North America Vaccine for Influenza Sales Quantity by Type (2018-2034)
6.2.2 North America Vaccine for Influenza Revenue by Type (2018-2034)
6.3 North America Vaccine for Influenza Market Size by Application
6.3.1 North America Vaccine for Influenza Sales Quantity by Application (2018-2034)
6.3.2 North America Vaccine for Influenza Revenue by Application (2018-2034)
6.4 North America Vaccine for Influenza Market Size by Country
6.4.1 North America Vaccine for Influenza Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Vaccine for Influenza Revenue by Country (2018-2034)
6.4.3 North America Vaccine for Influenza Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Vaccine for Influenza Sales by Company
7.1.1 Europe Vaccine for Influenza Sales Quantity by Company (2018-2024)
7.1.2 Europe Vaccine for Influenza Revenue by Company (2018-2024)
7.2 Europe Vaccine for Influenza Market Size by Type
7.2.1 Europe Vaccine for Influenza Sales Quantity by Type (2018-2034)
7.2.2 Europe Vaccine for Influenza Revenue by Type (2018-2034)
7.3 Europe Vaccine for Influenza Market Size by Application
7.3.1 Europe Vaccine for Influenza Sales Quantity by Application (2018-2034)
7.3.2 Europe Vaccine for Influenza Revenue by Application (2018-2034)
7.4 Europe Vaccine for Influenza Market Size by Country
7.4.1 Europe Vaccine for Influenza Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Vaccine for Influenza Revenue by Country (2018-2034)
7.4.3 Europe Vaccine for Influenza Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Vaccine for Influenza Sales by Company
8.1.1 China Vaccine for Influenza Sales Quantity by Company (2018-2024)
8.1.2 China Vaccine for Influenza Revenue by Company (2018-2024)
8.2 China Vaccine for Influenza Market Size by Type
8.2.1 China Vaccine for Influenza Sales Quantity by Type (2018-2034)
8.2.2 China Vaccine for Influenza Revenue by Type (2018-2034)
8.3 China Vaccine for Influenza Market Size by Application
8.3.1 China Vaccine for Influenza Sales Quantity by Application (2018-2034)
8.3.2 China Vaccine for Influenza Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Vaccine for Influenza Sales by Company
9.1.1 APAC Vaccine for Influenza Sales Quantity by Company (2018-2024)
9.1.2 APAC Vaccine for Influenza Revenue by Company (2018-2024)
9.2 APAC Vaccine for Influenza Market Size by Type
9.2.1 APAC Vaccine for Influenza Sales Quantity by Type (2018-2034)
9.2.2 APAC Vaccine for Influenza Revenue by Type (2018-2034)
9.3 APAC Vaccine for Influenza Market Size by Application
9.3.1 APAC Vaccine for Influenza Sales Quantity by Application (2018-2034)
9.3.2 APAC Vaccine for Influenza Revenue by Application (2018-2034)
9.4 APAC Vaccine for Influenza Market Size by Region
9.4.1 APAC Vaccine for Influenza Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Vaccine for Influenza Revenue by Region (2018-2034)
9.4.3 APAC Vaccine for Influenza Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaccine for Influenza Sales by Company
10.1.1 Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Vaccine for Influenza Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Vaccine for Influenza Market Size by Type
10.2.1 Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Vaccine for Influenza Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Vaccine for Influenza Market Size by Application
10.3.1 Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Vaccine for Influenza Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Vaccine for Influenza Market Size by Country
10.4.1 Middle East, Africa and Latin America Vaccine for Influenza Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Vaccine for Influenza Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Sanofi Vaccine for Influenza Products and Services
11.1.5 Sanofi Vaccine for Influenza SWOT Analysis
11.1.6 Sanofi Recent Developments
11.2 CSL
11.2.1 CSL Company Information
11.2.2 CSL Overview
11.2.3 CSL Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 CSL Vaccine for Influenza Products and Services
11.2.5 CSL Vaccine for Influenza SWOT Analysis
11.2.6 CSL Recent Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Overview
11.3.3 GSK Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 GSK Vaccine for Influenza Products and Services
11.3.5 GSK Vaccine for Influenza SWOT Analysis
11.3.6 GSK Recent Developments
11.4 Mylan
11.4.1 Mylan Company Information
11.4.2 Mylan Overview
11.4.3 Mylan Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Mylan Vaccine for Influenza Products and Services
11.4.5 Mylan Vaccine for Influenza SWOT Analysis
11.4.6 Mylan Recent Developments
11.5 Hulan Bio
11.5.1 Hulan Bio Company Information
11.5.2 Hulan Bio Overview
11.5.3 Hulan Bio Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Hulan Bio Vaccine for Influenza Products and Services
11.5.5 Hulan Bio Vaccine for Influenza SWOT Analysis
11.5.6 Hulan Bio Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Company Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 AstraZeneca Vaccine for Influenza Products and Services
11.6.5 AstraZeneca Vaccine for Influenza SWOT Analysis
11.6.6 AstraZeneca Recent Developments
11.7 CCBIO
11.7.1 CCBIO Company Information
11.7.2 CCBIO Overview
11.7.3 CCBIO Vaccine for Influenza Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 CCBIO Vaccine for Influenza Products and Services
11.7.5 CCBIO Vaccine for Influenza SWOT Analysis
11.7.6 CCBIO Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Vaccine for Influenza Value Chain Analysis
12.2 Vaccine for Influenza Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccine for Influenza Production Mode & Process
12.4 Vaccine for Influenza Sales and Marketing
12.4.1 Vaccine for Influenza Sales Channels
12.4.2 Vaccine for Influenza Distributors
12.5 Vaccine for Influenza Customers
13 Market Dynamics
13.1 Vaccine for Influenza Industry Trends
13.2 Vaccine for Influenza Market Drivers
13.3 Vaccine for Influenza Market Challenges
13.4 Vaccine for Influenza Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Vaccine for Influenza Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Trivalent Influenza Vaccine
Table 3. Major Manufacturers of Quadrivalent Influenza Vaccine
Table 4. Global Vaccine for Influenza Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Vaccine for Influenza Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Vaccine for Influenza Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Vaccine for Influenza Revenue Market Share by Region (2018-2024)
Table 8. Global Vaccine for Influenza Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Vaccine for Influenza Revenue Market Share by Region (2024-2034)
Table 10. Global Vaccine for Influenza Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Vaccine for Influenza Sales by Region (2018-2024) & (K Units)
Table 12. Global Vaccine for Influenza Sales Market Share by Region (2018-2024)
Table 13. Global Vaccine for Influenza Sales by Region (2024-2034) & (K Units)
Table 14. Global Vaccine for Influenza Sales Market Share by Region (2024-2034)
Table 15. Global Vaccine for Influenza Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Vaccine for Influenza Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Vaccine for Influenza Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Vaccine for Influenza Revenue Share by Manufacturers (2018-2024)
Table 19. Global Vaccine for Influenza Price by Manufacturers 2018-2024 (US$/Unit)
Table 20. Global Key Players of Vaccine for Influenza, Industry Ranking, 2021 VS 2022
Table 21. Global Vaccine for Influenza Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Vaccine for Influenza by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vaccine for Influenza as of 2022)
Table 23. Global Key Manufacturers of Vaccine for Influenza, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Vaccine for Influenza, Product Offered and Application
Table 25. Global Key Manufacturers of Vaccine for Influenza, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Vaccine for Influenza Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Vaccine for Influenza Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Vaccine for Influenza Sales Quantity Share by Type (2018-2024)
Table 30. Global Vaccine for Influenza Sales Quantity Share by Type (2024-2034)
Table 31. Global Vaccine for Influenza Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Vaccine for Influenza Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Vaccine for Influenza Revenue Share by Type (2018-2024)
Table 34. Global Vaccine for Influenza Revenue Share by Type (2024-2034)
Table 35. Vaccine for Influenza Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Vaccine for Influenza Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Vaccine for Influenza Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Vaccine for Influenza Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Vaccine for Influenza Sales Quantity Share by Application (2018-2024)
Table 40. Global Vaccine for Influenza Sales Quantity Share by Application (2024-2034)
Table 41. Global Vaccine for Influenza Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Vaccine for Influenza Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Vaccine for Influenza Revenue Share by Application (2018-2024)
Table 44. Global Vaccine for Influenza Revenue Share by Application (2024-2034)
Table 45. Vaccine for Influenza Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Vaccine for Influenza Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. North America Vaccine for Influenza Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Vaccine for Influenza Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Vaccine for Influenza Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Vaccine for Influenza Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Vaccine for Influenza Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Vaccine for Influenza Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Vaccine for Influenza Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Vaccine for Influenza Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Vaccine for Influenza Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Vaccine for Influenza Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Vaccine for Influenza Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Vaccine for Influenza Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Vaccine for Influenza Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Vaccine for Influenza Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Vaccine for Influenza Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Vaccine for Influenza Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Vaccine for Influenza Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Vaccine for Influenza Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Vaccine for Influenza Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Vaccine for Influenza Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Vaccine for Influenza Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Vaccine for Influenza Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Vaccine for Influenza Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Vaccine for Influenza Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Vaccine for Influenza Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Vaccine for Influenza Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Vaccine for Influenza Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Vaccine for Influenza Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Vaccine for Influenza Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Vaccine for Influenza Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Vaccine for Influenza Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Vaccine for Influenza Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Vaccine for Influenza Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Vaccine for Influenza Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Vaccine for Influenza Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Vaccine for Influenza Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Vaccine for Influenza Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Vaccine for Influenza Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Vaccine for Influenza Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Vaccine for Influenza Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Vaccine for Influenza Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Vaccine for Influenza Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Vaccine for Influenza Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Vaccine for Influenza Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Vaccine for Influenza Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Vaccine for Influenza Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Vaccine for Influenza Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Vaccine for Influenza Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Vaccine for Influenza Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Vaccine for Influenza Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Vaccine for Influenza Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Vaccine for Influenza Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Vaccine for Influenza Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Vaccine for Influenza Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Vaccine for Influenza Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Vaccine for Influenza Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Sanofi Company Information
Table 118. Sanofi Description and Overview
Table 119. Sanofi Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 120. Sanofi Vaccine for Influenza Product and Services
Table 121. Sanofi Vaccine for Influenza SWOT Analysis
Table 122. Sanofi Recent Developments
Table 123. CSL Company Information
Table 124. CSL Description and Overview
Table 125. CSL Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 126. CSL Vaccine for Influenza Product and Services
Table 127. CSL Vaccine for Influenza SWOT Analysis
Table 128. CSL Recent Developments
Table 129. GSK Company Information
Table 130. GSK Description and Overview
Table 131. GSK Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 132. GSK Vaccine for Influenza Product and Services
Table 133. GSK Vaccine for Influenza SWOT Analysis
Table 134. GSK Recent Developments
Table 135. Mylan Company Information
Table 136. Mylan Description and Overview
Table 137. Mylan Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 138. Mylan Vaccine for Influenza Product and Services
Table 139. Mylan Vaccine for Influenza SWOT Analysis
Table 140. Mylan Recent Developments
Table 141. Hulan Bio Company Information
Table 142. Hulan Bio Description and Overview
Table 143. Hulan Bio Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 144. Hulan Bio Vaccine for Influenza Product and Services
Table 145. Hulan Bio Vaccine for Influenza SWOT Analysis
Table 146. Hulan Bio Recent Developments
Table 147. AstraZeneca Company Information
Table 148. AstraZeneca Description and Overview
Table 149. AstraZeneca Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 150. AstraZeneca Vaccine for Influenza Product and Services
Table 151. AstraZeneca Vaccine for Influenza SWOT Analysis
Table 152. AstraZeneca Recent Developments
Table 153. CCBIO Company Information
Table 154. CCBIO Description and Overview
Table 155. CCBIO Vaccine for Influenza Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 156. CCBIO Vaccine for Influenza Product and Services
Table 157. CCBIO Vaccine for Influenza SWOT Analysis
Table 158. CCBIO Recent Developments
Table 159. Key Raw Materials Lists
Table 160. Raw Materials Key Suppliers Lists
Table 161. Vaccine for Influenza Distributors List
Table 162. Vaccine for Influenza Customers List
Table 163. Vaccine for Influenza Market Trends
Table 164. Vaccine for Influenza Market Drivers
Table 165. Vaccine for Influenza Market Challenges
Table 166. Vaccine for Influenza Market Restraints
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine for Influenza Product Picture
Figure 2. Global Vaccine for Influenza Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Vaccine for Influenza Market Share by Type in 2022 & 2034
Figure 4. Trivalent Influenza Vaccine Product Picture
Figure 5. Quadrivalent Influenza Vaccine Product Picture
Figure 6. Global Vaccine for Influenza Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Vaccine for Influenza Market Share by Application in 2022 & 2034
Figure 8. For Children (6 months to 3 years)
Figure 9. For Adults and Children over 3 years
Figure 10. Vaccine for Influenza Report Years Considered
Figure 11. Global Vaccine for Influenza Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Vaccine for Influenza Revenue 2018-2034 (US$ Million)
Figure 13. Global Vaccine for Influenza Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 14. Global Vaccine for Influenza Sales Quantity 2018-2034 (K Units)
Figure 15. Global Vaccine for Influenza Sales Quantity Market Share by Region (2018-2024)
Figure 16. Global Vaccine for Influenza Sales Quantity Market Share by Region (2024-2034)
Figure 17. North America Vaccine for Influenza Sales Quantity YoY (2018-2034) & (K Units)
Figure 18. North America Vaccine for Influenza Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Vaccine for Influenza Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. Europe Vaccine for Influenza Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Vaccine for Influenza Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. China Vaccine for Influenza Revenue YoY (2018-2034) & (US$ Million)
Figure 23. APAC Vaccine for Influenza Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. APAC Vaccine for Influenza Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Vaccine for Influenza Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Vaccine for Influenza Sales Quantity in 2022
Figure 28. The Top 10 and Top 5 Players Market Share by Vaccine for Influenza Revenue in 2022
Figure 29. Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
Figure 31. Global Vaccine for Influenza Revenue Market Share by Type (2018-2034)
Figure 32. Global Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
Figure 33. Global Vaccine for Influenza Revenue Market Share by Application (2018-2034)
Figure 34. North America Vaccine for Influenza Revenue Market Share by Company in 2022
Figure 35. North America Vaccine for Influenza Sales Quantity Market Share by Company in 2022
Figure 36. North America Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
Figure 37. North America Vaccine for Influenza Revenue Market Share by Type (2018-2034)
Figure 38. North America Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
Figure 39. North America Vaccine for Influenza Revenue Market Share by Application (2018-2034)
Figure 40. North America Vaccine for Influenza Revenue Share by Country (2018-2034)
Figure 41. North America Vaccine for Influenza Sales Quantity Share by Country (2018-2034)
Figure 42. U.S. Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Vaccine for Influenza Sales Quantity Market Share by Company in 2022
Figure 45. Europe Vaccine for Influenza Revenue Market Share by Company in 2022
Figure 46. Europe Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
Figure 47. Europe Vaccine for Influenza Revenue Market Share by Type (2018-2034)
Figure 48. Europe Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
Figure 49. Europe Vaccine for Influenza Revenue Market Share by Application (2018-2034)
Figure 50. Europe Vaccine for Influenza Revenue Share by Country (2018-2034)
Figure 51. Europe Vaccine for Influenza Sales Quantity Share by Country (2018-2034)
Figure 52. Germany Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 53. France Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 54. U.K. Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 57. China Vaccine for Influenza Sales Quantity Market Share by Company in 2022
Figure 58. China Vaccine for Influenza Revenue Market Share by Company in 2022
Figure 59. China Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
Figure 60. China Vaccine for Influenza Revenue Market Share by Type (2018-2034)
Figure 61. China Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
Figure 62. China Vaccine for Influenza Revenue Market Share by Application (2018-2034)
Figure 63. APAC Vaccine for Influenza Sales Quantity Market Share by Company in 2022
Figure 64. APAC Vaccine for Influenza Revenue Market Share by Company in 2022
Figure 65. APAC Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
Figure 66. APAC Vaccine for Influenza Revenue Market Share by Type (2018-2034)
Figure 67. APAC Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
Figure 68. APAC Vaccine for Influenza Revenue Market Share by Application (2018-2034)
Figure 69. APAC Vaccine for Influenza Revenue Share by Region (2018-2034)
Figure 70. APAC Vaccine for Influenza Sales Quantity Share by Region (2018-2034)
Figure 71. Japan Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 72. South Korea Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 73. China Taiwan Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 74. Southeast Asia Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 75. India Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity Market Share by Company in 2022
Figure 77. Middle East, Africa and Latin America Vaccine for Influenza Revenue Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity Market Share by Type (2018-2034)
Figure 79. Middle East, Africa and Latin America Vaccine for Influenza Revenue Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity Market Share by Application (2018-2034)
Figure 81. Middle East, Africa and Latin America Vaccine for Influenza Revenue Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Vaccine for Influenza Sales Quantity Share by Country (2018-2034)
Figure 83. Middle East, Africa and Latin America Vaccine for Influenza Revenue Share by Country (2018-2034)
Figure 84. Brazil Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 85. Mexico Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 86. Turkey Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 87. Israel Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 88. GCC Countries Vaccine for Influenza Revenue (2018-2034) & (US$ Million)
Figure 89. Vaccine for Influenza Value Chain
Figure 90. Vaccine for Influenza Production Process
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed